// App-Quantinova.ai

171 : Next-Generation NAMPT Inhibitors For ALL Identified By Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens

Researchers

Presenter

  • Michael C. Wei

Principal Investigators

  • Christina J. Matheny

  • Michael C. Bassik

  • Michael T. McManus

  • Jonathan S. Weissman

  • Michael L. Cleary

  • Alicia J. Donnelly

  • Martin Kampmann

  • Masayuki Iwasaki

  • Obdulio Piloto

  • David E. Solow-Cordero

  • Donna Bouley

  • Rachel E. Rau

  • Patrick Brown

Medical Centers

  • University of California, San Francisco, San Francisco, CA

  • Pediatric Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD

  • Johns Hopkins University, Baltimore, MD

  • University of California, San Francisco, San Francisco, CA

  • Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

  • Lung disease, immunodeficiency, and chromosome breakage syndrome

Biomarkers

  • Histone-lysine N-methyltransferase 2A

Drug/Treatment

  • Nicotinamide

  • folitixorin calcium

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved